evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

6 questions · 6 findings · 1 reviews · Gut

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 2 · 33.3%GRADE not reported 0 · 0%Very low 1 · 16.7%Low 1 · 16.7%Moderate 2 · 33.3%High 0 · 0%

Infliximab combined with purine analogues vs purine analogues

Clinical relapse · Participants with Crohn's disease in remission

Infliximab combined with purine analogues probably leads to lower clinical relapse (at 48 weeks, CDAI of 150 or greater together with… compared with purine analogues (moderate certainty).

1 finding from 1 review

Subcutaneous CT‐P13 and purine analogues vs intravenous CT‐P13 and purine analogues

Clinical relapse · patients with Crohn's disease (active disease population with clinical response at baseline)

It is very uncertain whether subcutaneous CT‐P13 and purine analogues changes clinical relapse (at 22 weeks, CDAI > 150) compared with intravenous CT‐P13 and purine analogues (very low certainty).

1 finding from 1 review